Bengaluru-based Strides Pharma Science has announced that its step‐down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into an exclusive partnership with US-based Ennaid Therapeutics, a global pharmaceutical company to produce an oral, repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19.   

Ennaid’s partnership with discovery scientists at Universidad Católica de Murcia (UCAM), identified a therapeutic target to treat COVID‐19 using artificial intelligence drug discovery platforms.

Initial tests show antiviral activity effective against SARS CoV‐2, the virus that causes COVID‐19, by inhibiting 90% of the virus' replication in vitro studies.

These results are so compelling that Ennaid is ready to seek emergency authorization from the FDA in the United States as well an approval for compassionate use in India.

Strides will be the exclusive manufacturing partner to Ennaid for the product.  

Dr R Ananthanarayanan, Managing Director and Group CEO, Strides, stated: “We are pleased to partner with Ennaid as an exclusive manufacturer of its oral repurposed medication to treat mild, moderate and asymptomatic cases of COVID‐19. At Strides we are committed in our fight against COVID‐19 and are working on creating a portfolio of products to aid COVID treatment and supportive care. Partnership with Ennaid is part of our initiative to provide quality and affordable treatment to the global patient pool impacted by COVID‐19.”